The new drug is the best evidence yet that biotech companies are likely to be drawn into the fight against bioterror, thanks to stripped-down U.S. regulations that make it easier to get drugs approved to treat diseases like anthrax and smallpox.
FORBES: Genomics Pioneer Takes On Anthrax